`
`
`
`SUPPLEMENTAL EXHIBIT 2054
`
`SUPPLEMENTAL EXHIBIT 2054
`
`
`
`On Behalf Of:
`
`Novartis AG and LTS Lohmann Therapie-Systeme AG
`
`By:
`
`Raymond R. Mandra
`ExelonPatchIPR@fchs.com
`(212) 218-2100
`
`UNITED STATES PATENT AND TRADEMARK OFFICE
`
`BEFORE THE PATENT TRIAL AND APPEAL BOARD
`
`NOVEN PHARMACEUTICALS INC.,
`Petitioner
`
`v.
`
`NOVARTIS AG AND LTS LOHMANN THERAPIE-SYSTEME AG,
`Patent Owners
`
`Inter Partes Review No. 2014-00549
`
`U.S. Patent 6,316,023
`
`Declaration of Lisa Butler
`
`
`
`I, Lisa Butler, declare as follows:
`
`1.
`
`I am an attorney at Fitzpatrick, Cella, Harper and Scinto,
`
`counsel for Novartis Pharmaceuticals Corporation, Novartis AG, Novartis Pharma
`
`AG and LTS Lohmann Therapie-Systeme AG (collectively, “Novartis”) in the
`
`above-captioned action. My attorney registration number is 63,828.
`
`I respectfully
`
`submit this declaration in support of Patent Owners’ Exhibit 2047*.
`
`2.
`
`Exhibit 2047 is a true and correct copy of search results
`
`obtained by me after entering the search terms “butylated” and “tocopherol” into
`
`the US. Food and Drug Administration Inactive Ingredient Search for Approved
`
`Drug Products available at http://www.accessdata.fda.gov/scripts/cder/iig/ on
`
`December 30, 2014.
`
`I declare under penalty of perjury that the foregoing is true and
`
`correct.
`
`Dated:
`
`February 10, 2015
`
`CXflm saw/v
`
`Lisa Butler
`
`NOVARTIS EXHIBIT 2054
`Noven v. Novartis and LTS Lohmann
`|PR2014-00549
`Page 2 of 2
`
`